Open-label parallel dose tolerability study of three subcutaneous immunotherapy regimens in house dust mite allergic patients

BACKGROUND: The current maintenance dose (10,000 AUeq/monthly) of a subcutaneous allergoid for house dust mite (HDM) immunotherapy has previously shown significant clinical efficacy in patients with HDM induced allergic rhinitis or rhinoconjunctivitis. In order to comply with the 2009 EMA guidelines...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Rieker-Schwienbacher, Juliane, Nell, Marja J, Diamant, Zuzana, van Ree, Ronald, Distler, Andreas, Boot, Johan D, Kleine-Tebbe, Jörg
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2013
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3658910/
https://ncbi.nlm.nih.gov/pubmed/23657148
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2045-7022-3-16
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados